Inclusion Criteria:

- Patients must have a confirmed diagnosis of CLL or small lymphocytic lymphoma (SLL)
based upon the Revised NCI-sponsored Working Group guidelines for CLL;

- Relapsed or refractory disease after previous chemotherapy treatment;

- Age > 18 years;

- Adequate renal function with creatinine <= 1.5 mg/dL;

- Adequate liver function with alkaline phosphatase <= 2.5 X upper limit of normal,
serum glutamic oxaloacetic transaminase (SGOT), and serum glutamic pyruvic
transaminase (SGPT) <= 2.5 X upper limit of normal; and total bilirubin <= 2.0 X
upper limit of normal;

- Adequate bone marrow function as determined by having platelets > 50,000/mm3 without
transfusion in the preceding 2 weeks and an absolute neutrophil count (ANC) => 1,500
cells/mm3 without growth factor support; unless cytopenias due to marrow
infiltration;

- Able to give informed consent;

- A minimum of 4 weeks must have elapsed from the completion of any previous treatment
regimen, including radiation and biologic therapies (6 weeks if a prior nitrosourea
or mitomycin C, 12 weeks if radioimmunotherapy) to treatment on Day 1 Cycle 1.
Patients must have recovery from treatment-associated toxicity(ies);

- A predicted life expectancy of at least 6 months; and

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

Exclusion Criteria:

- More than three systemic treatment regimens for CLL/SLL (excluding immunotherapies
and biologic therapies);

- Concurrent malignancy that the patient has not been free of for at least 5 years,
excluding curatively treated carcinoma-in-situ or non-melanoma skin cancer;

- Any pregnant or lactating females. Females of childbearing potential must have a
negative pregnancy test and all male and female patients of reproductive potential
must agree to use adequate birth control;

- Known HIV-positive patients;

- Any underlying medical conditions or circumstances that would contraindicate therapy
with study treatment, affect compliance or impair evaluation of study endpoints;

- Receiving investigational agents within 4 weeks of the study treatment; and

- Known allergy to reagents in the study.